Recently, therapeutic modulators that induce CXCL10 and CXCL9 expression were reported to improve immune cell responses and TME in ovarian cancer (Bronger et al., 2016; Au et al., 2017). This evidence concerns the gene CXCL9 and ovarian carcinoma.